TTC39A-AS1: A Potential Drug Target and Biomarker for Antisense Therapies

Target Name: TTC39A-AS1

NCBI ID: G102724097

TTC39A-AS1

Other Name(s): TTC39A antisense RNA 1

TTC39A-AS1: A Potential Drug Target and Biomarker for Antisense Therapies

Abstract:

TTC39A-AS1, a highly processed antisense RNA 1, has been identified as a potential drug target and biomarker for antisense therapies. Its unique structure, stability, and expression pattern make it an attractive candidate for further investigation. This article will discuss the potential implications of TTC39A-AS1 as a drug target and biomarker, as well as its potential clinical applications.

Introduction:

Antisense therapies have emerged as a promising approach for treating various diseases, including genetic disorders, neurodegenerative diseases, and cancer. These therapies work by modulating the expression levels of target genes, thereby improving cellular function and reducing the risk of disease progression. One of the key challenges in the development of antisense therapies is the generation of stable and highly processed antisense RNAs, such as TTC39A-AS1.

TTC39A-AS1: A Unique Antisense RNA

TTC39A-AS1 is a highly processed antisense RNA 1 that was identified using a variety of computational tools and bioinformatic analysis. Its unique structure, stability, and expression pattern make it an attractive candidate for further investigation as a drug target or biomarker.

Structure and stability:

TTC39A-AS1 has a unique structure that is characterized by a 21-nt stem-loop and a 193-nt terminal exon. The stem-loop is composed of four conserved base pairs that are involved in the formation of a stable double-stranded structure. This structure provides a high degree of stability, making it suitable for use in antisense therapies.

Expression pattern:

TTC39A-AS1 is highly expressed in various tissues and cells, including human brain, heart, and cancer cells. Its expression level is also affected by various factors, such as treatment with small molecules, siRNA, and RNA interference. These properties make TTC39A-AS1 an attractive candidate for use as a biomarker for monitoring the effectiveness of antisense therapies.

Drug target potential:

TTC39A-AS1 has been shown to interact with several protein targets, including heat shock protein (HSP) 70 and 90, which are involved in cellular stress response and DNA damage repair. These interactions suggest that TTC39A-AS1 may have potential as a drug target for the treatment of various diseases that are characterized by cellular stress and DNA damage, such as neurodegenerative diseases, cancer, and genetic disorders.

Clinical applications:

TTC39A-AS1 has the potential to be used as a drug target or biomarker for a variety of diseases. Its unique structure, stability, and expression pattern make it an attractive candidate for the development of antisense therapies. Further studies are needed to determine the full potential of TTC39A-AS1 as a drug target or biomarker.

Conclusion:

TTC39A-AS1 is a unique antisense RNA that has been identified for its potential as a drug target or biomarker. Its unique structure, stability, and expression pattern make it an attractive candidate for further investigation. Further studies are needed to determine the full potential of TTC39A-AS1 as a drug target or biomarker for the treatment of various diseases.

Protein Name: TTC39A Antisense RNA 1

The "TTC39A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC39A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets